{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:22:31Z","timestamp":1780626151582,"version":"3.54.1"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.eplepsyres.2022.107030","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T02:19:56Z","timestamp":1664504396000},"page":"107030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Effect of Lacosamide therapy on blood cells and IgA levels in children and adolescents with epilepsy in a clinical setting"],"prefix":"10.1016","volume":"187","author":[{"given":"Yuichi","family":"Tateishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutsune","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Izumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2022.107030_bib1","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1111\/epi.16381","article-title":"Long\u2010term safety and efficacy of lacosamide and controlled\u2010release carbamazepine monotherapy in patients with newly diagnosed epilepsy","volume":"60","author":"Ben-Menachem","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2022.107030_bib2","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/epi.13777","article-title":"Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy","volume":"58","author":"Berghuis","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2022.107030_bib3","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1203\/PDR.0b013e318232169e","article-title":"Slow salivary secretory IgA maturation may relate to low microbial pressure and allergic symptoms in sensitized children","volume":"70","author":"Fager\u00e5s","year":"2011","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.eplepsyres.2022.107030_bib4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.seizure.2019.05.016","article-title":"Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures \u2013 an open-label trial","volume":"71","author":"Ferreira","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2022.107030_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106447","article-title":"Effects of perampanel add-on therapy on immunoglobulin levels in pediatric patients with epilepsy","volume":"167","author":"Ishikawa","year":"2020","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2022.107030_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108614","article-title":"Clinical impact of the dose and blood concentration of lacosamide in Japanese pediatric patients with epilepsy: a cohort study","volume":"129","author":"Ishikawa","year":"2022","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2022.107030_bib7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/17425255.2022.2075342","article-title":"Individualizing doses of antiepileptic drugs","volume":"18","author":"Liparoti","year":"2022","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.eplepsyres.2022.107030_bib8","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1111\/epi.16745","article-title":"Effects of lacosamide and carbamazepine on lipids in a randomized trial","volume":"61","author":"Mintzer","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2022.107030_bib9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/epi.17117","article-title":"Antiseizure medications and thyroid hormone homeostasis: literature review and practical recommendations","volume":"63","author":"Rochtus","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2022.107030_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2014.11.021","article-title":"Current understanding of the mechanism of action of the antiepileptic drug lacosamide","volume":"110","author":"Rogawski","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2022.107030_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.coi.2012.03.005","article-title":"IgA synthesis: a form of functional immune adaptation extending beyond gut","volume":"24","author":"Sutherland","year":"2012","journal-title":"Curr. Opin. Immunol."},{"issue":"suppl. 196","key":"10.1016\/j.eplepsyres.2022.107030_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/ane.12044","article-title":"Reduced immunoglobulin levels in epilepsy patients treated with levetiracetam, lamotrigine, or carbamazepine","volume":"127","author":"Svalheim","year":"2013","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"10.1016\/j.eplepsyres.2022.107030_bib13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1440-1754.1997.tb01588.x","article-title":"Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants","volume":"33","author":"Verrotti","year":"1997","journal-title":"J. Paediatr. Child Health"},{"key":"10.1016\/j.eplepsyres.2022.107030_bib14","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2362.2004.01311.x","article-title":"Gender, age and seasonal effects on IgA deficiency: a study of 7293 Caucasians","volume":"34","author":"Weber-Mzell","year":"2004","journal-title":"Eur. J. Clin. Invest."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121122001814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121122001814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:48:20Z","timestamp":1760276900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121122001814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":14,"alternative-id":["S0920121122001814"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.107030","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Lacosamide therapy on blood cells and IgA levels in children and adolescents with epilepsy in a clinical setting","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.107030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107030"}}